12.18
12.18 (-0.23%)
As of Jun 14, 2022
Nkarta, Inc. [NKTX]
Source:
Company Overview
We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (“NK”), cell therapies to treat cancer. Our NK cell engineering platform builds on prior experience and success with engineering T cells and includes proprietary technologies that enable us to generate an abundant supply of NK cells, improve the persistence of these cells for sustained activity in the body, engineer enhanced NK cell recognition of tumor targets and to freeze, store and thaw our engineered NK cells for off-the-shelf use for the treatment of cancer.
Country | United States |
Headquarters | south san francisco, california |
Phone Number | (925) 407-1049 |
Industry | manufacturing |
CEO | Paul J. Hastings |
Website | www.clintrials.gov |